Aplastic Anemia Treatment Market - Top Companies and Manufacturers

  • Report ID: 3799
  • Published Date: Jun 07, 2024
  • Report Format: PDF, PPT

Companies Dominating the Aplastic Anemia Treatment Landscape

top-features-companies
    • F. Hoffmann-La Roche Ltd.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Eisai Co., Ltd.
    • Allergan, Inc.
    • TauRx Therapeutics Ltd.
    • AbbVie Inc.
    • Novartis AG
    • Siemens Healthcare GmbH
    • Pfizer, Inc.
    • Bristol-Myers Squibb Company
    • Bayers AG

Browse Key Market Insights with Data Illustration:

In the News

  • Sandoz announced the acquisition of GSK's cephalosporin antibiotic business to expand its collection of antimicrobials. This acquisition allows Sandoz to increase its portfolio of antibiotics, which is beneficial for both Sandoz and the patients they serve. The acquisition also gives Sandoz access to GSK's patented technology, which will help them stay competitive in the industry.

  • In Europe, the European Commission approved the consolidation of Mylan and Upjohn between Pfizer and Mylan. Combining Mylan's generics market presence with Pfizer's branded market presence will enable the companies to create a new global healthcare leader.


Author Credits:  Radhika Pawar


  • Report ID: 3799
  • Published Date: Jun 07, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2024, the industry size of aplastic anemia treatment is assessed at USD 7 Billion.

The aplastic anemia treatment market size was over USD 6.72 Billion in 2023 and is likely to reach USD 12.45 Billion by the end of 2036, witnessing around 5.1% CAGR during the forecast period i.e., between 2024-2036. The increasing number of people being diagnosed with aplastic anemia, improved access to healthcare, and the availability of new and improved treatment options are the major factors expected to drive the market growth.

North America is projected to hold the largest industry share by 2036, due to the availability of advanced treatment options for aplastic anemia, such as bone marrow transplantation, immunosuppressive therapy, and blood transfusions.

F. Hoffmann-La Roche Ltd., Eisai Co., Ltd., Allergan, Inc., TauRx Therapeutics Ltd., AbbVie Inc., Novartis AG, Siemens Healthcare GmbH, Pfizer, Inc., Bristol-Myers Squibb Company, Bayers AG
Inquiry Before Buying Request Free Sample
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying